Latest Intelligence on Pharmaceuticals in North America

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

ZymoGenetics: early hope for late-stage disease

ZymoGenetics has reported positive results from its phase Ia study of IL-21 in patients with metastatic melanoma and metastatic renal cell carcinoma. This announcement warrants further studies of IL-21 in these indications, which is welcome news for ZymoGenetics and development partner Novo Nordisk. However, competition is already on the horizon, in the form of Bayer/Onyx' Nexavar.

Published By Datamonitor
15 Nov 2005
Expert View
Expert View

Zelboraf's approval demonstrates a significant shift toward personalized cancer therapy

The FDA has approved Zelboraf and Roche's companion diagnostic test for BRAF V600E mutation-positive metastatic melanoma. The joint approval is the first example of co-development and demonstrates the movement toward personalized cancer therapy, and Zelboraf's impressive efficacy data and the availability of a test will ensure rapid uptake.

Published By Datamonitor
18 Aug 2011
Expert View
Expert View

Xarelto data raise questions at the 2010 American Heart Association Scientific Sessions

Results from the ROCKET-AF trial of Xarelto in stroke prevention in atrial fibrillation have been presented at this year's Scientific Sessions of the American Heart Association. While positive, the data show that Xarelto has by no means outperformed Pradaxa. Clinicians may start to see the two drugs as complementary alternatives, based on their respective performance in various subgroups.

Published By Datamonitor
16 Nov 2010
CommentWire
CommentWire

Xanthus: more hurdles to clear for Symadex

Xanthus Life Sciences has begun dosing patients in a phase II trial of Symadex in recurrent colorectal cancer. While this is clearly a positive step in Symandex' development, the drug candidate still has phase III trials to contend with and, even if Symandex proves fit for launch here, Xanthus will need to find a marketing partner to help it achieve commercial success in the tough cancer market.

Published By Datamonitor
17 Jan 2006
CommentWire
CommentWire

Wyeth: positive Aprela results bode well for planned portfolio strategy

Wyeth has announced new positive Phase III data for its menopause treatment Aprela. The potential blockbuster is well positioned to provide a unique approach to the treatment of menopausal symptoms in women at risk of developing osteoporosis, and assuming regulatory hurdles can be overcome, Aprela will help further maintain Wyeth's position as a leading women's health player.

Published By Datamonitor
29 Jul 2009
CommentWire
CommentWire

Wyeth: job cuts for US sales force

About 1,200 US sales representatives at Wyeth have been notified this week that they are to lose their positions. The cuts come as part of a major company-wide restructuring program, announced nine weeks ago. Like many of its peers, Wyeth's US sales are struggling against increased competition from generic products: a trend which is forecast to intensify over the next five years.

Published By Datamonitor
28 Mar 2008
CommentWire
CommentWire

Wyeth: breast cancer prospects receive a blow

Wyeth has discontinued a phase III trial of temsirolimus plus letrozole in metastatic post-menopausal hormone-receptor positive breast cancer. This is a significant blow for the company due to the loss of earnings potential in the congested but lucrative breast cancer market. However, temsirolimus remains under development for a number of other tumors, and so hope for the drug candidate remains.

Published By Datamonitor
23 Mar 2006
CommentWire
CommentWire

Wyeth: Big Pharma continues its shopping spree

The current economic environment has paved the way for leading pharmaceutical firms to sweep in and buy up smaller players, highlighted by Wyeth's potential acquisition of Crucell and Merck & Co's strategy to aggressively look for targets in 2009. An increasing number of pharmaceutical majors are likely to use this approach to strengthen their biologic portfolios and access novel pipeline drugs.

Published By Datamonitor
09 Jan 2009
CommentWire
CommentWire

Wyeth/MedImmune: the end of the road for FluMist venture

Following poor first-year performance, Wyeth [WYE] and MedImmune [MEDI] have announced the dissolution of their FluMist partnership. If MedImmune is to achieve success with this product alone, it may need to rethink its premium pricing strategy.

Published By Datamonitor
28 Apr 2004
CommentWire
CommentWire

Wyeth/MedImmune: second generation vaccine

Wyeth [WYE] and MedImmune's [MEDI] FluMist failed to secure indications for use in key target groups for influenza vaccine in the US. Recently released results suggest that their second generation product may enable the two companies to capitalize on more conventional influenza vaccine sectors.

Published By Datamonitor
15 Oct 2003

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.